Targeting the Ezrin Adaptor Protein Sensitizes Metastatic Breast Cancer Cells to Chemotherapy and Reduces Neoadjuvant Therapy-induced Metastasis.

While the percentage of apoptotic cells was higher for both DOX+NSC (14.9%) and DTX+NSC (15.2%) treatment groups compared with single-agent treatments (11.9%, 8.0%, and 10.4% for DOX, DTX, and NSC, respectively), these differences did not reach statistical significance ( Fig. 5D ).

also in 111,027 other papers